In the previously mentioned studies, MM patients had increased levels of IL-17 compared to controls; this could be related to the increased amounts of IL-6 in the bone marrow of myeloma patients with active disease which promotes the production of Th17 cells from CD4 naïve cells. Here, IL6 is linked to plasma cell myeloma.